tucatinib,trastuzumab
seagen
 exciting data for her2+ #crc at #wcgic2022 mountaineer: tucatinib/trastuzumab &gt;2 prior lines orr: 38.1%/dcr: 60% mdor: 12.4 mpfs 8.2 mos 24.1 51.3% of patients alive at 24mo #precisionmedicine 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine